Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Alden A. Moccia(BC Cancer Agency), Emanuele Zucca(Università della Svizzera italiana), Corinne Rusterholz(Swiss Group For Clinical Cancer Research), Felicitas Hitz(Kantonsspital St. Gallen), Daniel Vorobiof(The Medical Oncology Centre of Rosebank), Thomas Pabst(University Hospital of Bern), Sämi Schär(Swiss Group For Clinical Cancer Research), Michele Ghielmini(Institute of Oncology Research), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Walter Mingrone(Kantonsschule Olten), Céline Ruegsegger(Swiss Group For Clinical Cancer Research), Johann Raats(Kantonsspital St. Gallen), Auro del Giglio(Faculdade de Medicina do ABC), Andreas Lohri(Kantonsspital St. Gallen), Stéphanie Rondeau(Kantonsspital St. Gallen), Christine Biaggi Rudolf(Kantonsspital St. Gallen), Christian Taverna(Kantonsspital St. Gallen), Anna Vanazzi(European Institute of Oncology), Lidija Čevreska(Kantonsspital St. Gallen), Daniel Rauch(Washington University in St. Louis)
Cited by 25
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639